Izalontamab SI-B001 is an significant advance in hematologic care of relapsed multiple myeloma. This innovative antibody selectively interacts with BCMA of myeloma cells, inducing immune-mediated cellular cytotoxicity while enhancing anti-tumor body's responses. Early clinical data indicate encourag